RAPT THERAPEUTICS, INC. (RAPT) News
Filter RAPT News Items
RAPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RAPT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RAPT News From Around the Web
Below are the latest news stories about RAPT THERAPEUTICS INC that investors may wish to consider to help them evaluate RAPT as an investment opportunity.
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:0 |
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of DirectorsSOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a |
Rapt Therapeutics upgraded to Buy from Neutral at H.C. WainwrightH.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from Neutral with a $10 price target after Rapt and a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China, announced that they have entered into an exclusive license agreement for JYB1904, or RPT904, a clinical-stage, half-life extended anti-immunoglobulin E monoclonal antibody. Rapt plans to pursue development of RPT904 initially in food allergy, which is a market that represents “a large and lucrative niche,” |
Progressive, EverQuote upgraded: Wall Street's top analyst callsProgressive, EverQuote upgraded: Wall Street's top analyst calls |
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreementUnder the licence terms, Jemincare is set to obtain an upfront payment of $35m. |
Why RAPT Therapeutics Stock Gained Over 100% On Monday?RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical. The collaboration is for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. RPT904 is designed to provide a potential alternative to omalizumab (Xolair), addressing allergic conditions such as asthma and chronic spontaneous urticaria |
RAPT Therapeutics Announces $150 Million Private PlacementSOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $ |
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- |
RAPT Therapeutics Reports Third Quarter 2024 Financial ResultsSOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and nine months ended September 30, 2024. Financial Results for the Third Quarter and Nine Months Ended September 30, 20 |
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cullThe trials were placed on hold earlier this year due to a serious adverse event in a patient. |